Enhancing immunogenicity and reducing dose of microparticulated synthetic vaccines: single intradermal administration.
OBJECTIVE
Our purpose was to evaluate the ability of a polymeric vehicle to release a model synthetic vaccine to the skin in order to reach a potent activation of the specific immune response.


METHODS
The peptide-loaded poly-D,L-lactide-co-glycolide acid (PLGA) microparticles were prepared by a double emulsion technique and administered to Balb/c mice. The immune response (antibody and T cell activation) obtained by the intradermal (i.d.) and the subcutaneous (s.c.) routes was tested.


RESULTS
When similar doses of peptide-loaded microparticles were injected s.c. or i.d. in mice, the antipeptide IgG antibody immune response was found to be significantly higher after i.d. injection into the skin. We could also reduce the dose of antigen 10 times by the i.d. route and find a similar antibody response to that obtained by the s.c. immunization. At the lowest i.d. dose level, the IgG2a/IgG1 ratio was also incremented and the IgE production decreased. The i.d. microparticles induced, at both dose levels, a marked IFN-gamma secretion by peptide-stimulated splenocytes and lymph node cells and a significant T cell proliferation in spleen cell cultures.


CONCLUSIONS
The results demonstrate that peptide-loaded microparticles were efficiently administered by the i.d. route because lower doses were required and powerful antibody and T cell responses were obtained compared to the conventional s.c. administration.
Carcaboso
Angel M
AM
Pharmacy and Pharmaceutical Technology Laboratory, Faculty of Pharmacy, University of the Basque Country (UPV-EHU), Paseo de la Universidad no 7, 01006 Vitoria-Gasteiz, Spain.
Hernández
Rosa M
RM
Igartua
Manuela
M
Rosas
Jaiver E
JE
Patarroyo
Manuel E
ME
Pedraz
José L
JL
D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000818:Animals; D002455:Cell Division / Q000276:immunology; D004306:Dose-Response Relationship, Immunologic; D004334:Drug Administration Schedule; D007271:Injections, Intradermal; D007279:Injections, Subcutaneous; D019344:Lactic Acid / Q000008:administration & dosage / Q000276:immunology; D008213:Lymphocyte Activation / Q000276:immunology; D008214:Lymphocytes / Q000166:cytology / Q000187:drug effects / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D008863:Microspheres; D010316:Particle Size; D011100:Polyglycolic Acid / Q000008:administration & dosage; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011108:Polymers / Q000008:administration & dosage; D013154:Spleen / Q000187:drug effects / Q000276:immunology; D022223:Vaccines, Subunit / Q000008:administration & dosage* / Q000276:immunology*; D014614:Vaccines, Synthetic / Q000008:administration & dosage* / Q000276:immunology*
D000276:Adjuvants, Immunologic; D011108:Polymers; D022223:Vaccines, Subunit; D014614:Vaccines, Synthetic; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid